Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Antagonist G

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Antagonist G is a substance P analog, which is a broad spectrum neuropeptide growth factor antagonist and antiproliferative agent. It was developed for the treatment of small cell lung cancer. It could inhibit neuropeptide-dependent and -independent proliferation of small cell lung cancer in vitro. It also inhibits growth of SCLC xenografts in mice in vivo. It blocks Swiss 3T3 cell growth induced by vasopressin, gastrin-releasing peptide and bradykinin. It activates JNK and stimulates apoptosis. It is an anticancer agent and is resistant to degradation by peptidases.

Category

Peptide Inhibitors

Catalog number

BAT-006104

CAS number

115150-59-9

Molecular Formula

C49H66N12O6S

Molecular Weight

951.20

Size	Price	Stock	Quantity
1 mg	$439	In stock

Specification
Reference Reading

IUPAC Name

(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpentanamide

Synonyms

[Arg6,D-Trp7,9,N-MePhe8]-Substance P(6-11)

Purity

98%

Density

1.35 g/cm3

Sequence

H-Arg-D-Trp-N(Me)Phe-D-Trp-Leu-Met-NH2

Storage

Store at -20°C

InChI

InChI=1S/C49H66N12O6S/c1-29(2)23-39(45(64)57-38(43(51)62)20-22-68-4)58-46(65)40(25-31-27-55-36-18-10-8-15-33(31)36)59-47(66)42(24-30-13-6-5-7-14-30)61(3)48(67)41(26-32-28-56-37-19-11-9-16-34(32)37)60-44(63)35(50)17-12-21-54-49(52)53/h5-11,13-16,18-19,27-29,35,38-42,55-56H,12,17,20-26,50H2,1-4H3,(H2,51,62)(H,57,64)(H,58,65)(H,59,66)(H,60,63)(H4,52,53,54)/t35-,38-,39-,40+,41+,42-/m0/s1

InChI Key

CUCSSYAUKKIDJV-FAXBSAIASA-N

Canonical SMILES

CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC3=CC=CC=C3)N(C)C(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)C(CCCN=C(N)N)N

1.Determination of two neuropeptide growth factor antagonists, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P and [Arg6,D-Trp7,9,N-MePhe8]- substance P(6-11), by high-performance liquid chromatography with electrochemical detection.

Cummings J;MacLellan A;Langdon SP;Rozengurt E;Smyth JF J Chromatogr B Biomed Appl. 1994 Mar 4;653(2):195-203.

The neuropeptide growth factor antagonists [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P (D) and [Arg6,D-Trp7,9, [corrected] N-MePhe8]-substance P(6-11) (G) are currently undergoing preclinical evaluation as potential anticancer agents and clinical trials are planned for G in the near future. A reversed-phase high-performance liquid chromatographic separation has been developed which is both sensitive (limit of detection 250 pg/263 fmol for G; 500 pg/330 fmol for D) and selective, based on electrochemical detection of the two tryptophan residues present in each peptide. Two ion-pairing agents were included in the isocratic mobile phase to eliminate adsorption of the peptides onto the analytical column. Extensive sample clean-up procedures have been developed for plasma, tissue and tumour based on solid-phase extraction. Precision and accuracy of each assay was 91.3 +/- 16.9% (between-day) for G and 99.3 +/- 16.9% (between-day) for D. The assays were able to detect the intact peptides and a number of their metabolites in plasma, liver and the WX 322 SCLC human xenograft in nude mice for at least 6 hr after administration of therapeutic and pharmacological doses.